These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 31758471)

  • 1. Relevant Weight Reduction and Reversed Metabolic Co-morbidities Can Be Achieved by Duodenojejunal Bypass Liner in Adolescents with Morbid Obesity.
    Homan M; Kovač J; Orel R; Battelino T; Kotnik P
    Obes Surg; 2020 Mar; 30(3):1001-1010. PubMed ID: 31758471
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is duodeno-jejunal bypass liner superior to pylorus preserving bariatric surgery in terms of complications and efficacy?
    Balint IB; Csaszar F; Somodi K; Ternyik L; Biro A; Kaposztas Z
    Langenbecks Arch Surg; 2021 Aug; 406(5):1363-1377. PubMed ID: 33712874
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Open-label, sham-controlled trial of an endoscopic duodenojejunal bypass liner for preoperative weight loss in bariatric surgery candidates.
    Gersin KS; Rothstein RI; Rosenthal RJ; Stefanidis D; Deal SE; Kuwada TS; Laycock W; Adrales G; Vassiliou M; Szomstein S; Heller S; Joyce AM; Heiss F; Nepomnayshy D
    Gastrointest Endosc; 2010 May; 71(6):976-82. PubMed ID: 20304396
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glycemic control and BMI changes after endoscopic implantation of a duodenojejunal bypass liner compared with laparoscopic Roux-en-Y gastric bypass surgery: a propensity score matching analysis.
    Günthert SJ; Aksan A; Schröder O; Meyer G; Hausmann J; Stein J; Stier C
    Surg Endosc; 2022 Aug; 36(8):5979-5985. PubMed ID: 35378626
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and Safety of the Duodeno-Jejunal Bypass Liner in Patients With Metabolic Syndrome: A Multicenter Randomized Controlled Trial (ENDOMETAB).
    Caiazzo R; Branche J; Raverdy V; Czernichow S; Carette C; Robert M; Disse E; Barthet M; Cariou B; Msika S; Behal H; Denies F; Dervaux B; Duhamel A; Verkindt H; Pattou F
    Ann Surg; 2020 Nov; 272(5):696-702. PubMed ID: 32889869
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of the endoscopic duodenal-jejunal bypass liner on obesity and type 2 diabetes mellitus, a multicenter randomized controlled trial.
    Koehestanie P; de Jonge C; Berends FJ; Janssen IM; Bouvy ND; Greve JW
    Ann Surg; 2014 Dec; 260(6):984-92. PubMed ID: 25072436
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Weight loss and metabolic improvement in morbidly obese subjects implanted for 1 year with an endoscopic duodenal-jejunal bypass liner.
    Escalona A; Pimentel F; Sharp A; Becerra P; Slako M; Turiel D; Muñoz R; Bambs C; Guzmán S; Ibáñez L; Gersin K
    Ann Surg; 2012 Jun; 255(6):1080-5. PubMed ID: 22534421
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trends in BMI, Glycemic Control and Obesity-Associated Comorbidities After Explantation of the Duodenal-Jejunal Bypass Liner (DJBL).
    Riedel N; Laubner K; Lautenbach A; Schön G; Schlensak M; Stengel R; Eberl T; Dederichs F; Aberle J; Seufert J
    Obes Surg; 2018 Aug; 28(8):2187-2196. PubMed ID: 29504053
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Baseline glycated hemoglobin levels are associated with duodenal-jejunal bypass liner-induced weight loss in obese patients.
    Muñoz R; Dominguez A; Muñoz F; Muñoz C; Slako M; Turiel D; Pimentel F; Sharp A; Escalona A
    Surg Endosc; 2014 Apr; 28(4):1056-62. PubMed ID: 24196558
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative efficacy and safety of the duodenal-jejunal bypass liner in obese patients with type 2 diabetes mellitus: A case control study.
    Laubner K; Riedel N; Fink K; Holl RW; Welp R; Kempe HP; Lautenbach A; Schlensak M; Stengel R; Eberl T; Dederichs F; Schwacha H; Seufert J; Aberle J
    Diabetes Obes Metab; 2018 Aug; 20(8):1868-1877. PubMed ID: 29569313
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Effect of 6 and 12 months Duodenal-Jejunal Bypass Liner Treatment on Obesity and Type 2 Diabetes: a Crossover Cohort Study.
    van Rijn S; Betzel B; de Jonge C; van Dijk DPJ; Janssen IM; Berends FJ; Bouvy ND; Greve JWM
    Obes Surg; 2018 May; 28(5):1255-1262. PubMed ID: 29110244
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Longitudinal evaluation of efficacy, safety and nutritional status during one-year treatment with the duodenal-jejunal bypass liner.
    Riedel N; Laubner K; Lautenbach A; Schön G; Schlensak M; Stengel R; Eberl T; Dederichs F; Aberle J; Seufert J
    Surg Obes Relat Dis; 2018 Jun; 14(6):769-779. PubMed ID: 29650340
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and Effectiveness of an Endoscopically Placed Duodenal-Jejunal Bypass Device (EndoBarrier®): Outcomes in 114 Patients.
    Forner PM; Ramacciotti T; Farey JE; Lord RV
    Obes Surg; 2017 Dec; 27(12):3306-3313. PubMed ID: 29018990
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Weight reduction and improvement in diabetes by the duodenal-jejunal bypass liner: a 198 patient cohort study.
    Betzel B; Homan J; Aarts EO; Janssen IMC; de Boer H; Wahab PJ; Groenen MJM; Berends FJ
    Surg Endosc; 2017 Jul; 31(7):2881-2891. PubMed ID: 27804045
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is reimplantation of the duodenal-jejunal bypass liner feasible?
    Koehestanie P; Betzel B; Aarts EO; Janssen IM; Wahab P; Berends FJ
    Surg Obes Relat Dis; 2015; 11(5):1099-104. PubMed ID: 25979208
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sustained weight loss after duodenal-jejunal bypass liner treatment in patients with body mass index below, but not above 35 kg/m
    Boonchaya-Anant P; Bueter M; Gubler C; Gerber PA
    Clin Obes; 2023 Feb; 13(1):e12561. PubMed ID: 36239531
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of a duodenal-jejunal bypass liner on lipid profile and blood concentrations of long chain polyunsaturated fatty acids.
    Glaysher MA; Ward J; Aldhwayan M; Ruban A; Prechtl CG; Fisk HL; Chhina N; Al-Najim W; Smith C; Klimowska-Nassar N; Johnson N; Falaschetti E; Goldstone AP; Miras AD; Byrne JP; Calder PC; Teare JP
    Clin Nutr; 2021 Apr; 40(4):2343-2354. PubMed ID: 33131909
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of glucometric 'dynamical' variables on duodenal-jejunal bypass liner (DJBL) anthropometric and metabolic outcomes.
    Colás A; Varela M; Mraz M; Novak D; Cuesta-Frau D; Vigil L; Benes M; Pelikanova T; Haluzik M; Burda V; Vargas B
    Diabetes Metab Res Rev; 2020 May; 36(4):e3287. PubMed ID: 31916665
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of the Duodenal-Jejunal Bypass Liner on Glycemic Control in Patients With Type 2 Diabetes With Obesity: A Meta-analysis With Secondary Analysis on Weight Loss and Hormonal Changes.
    Jirapinyo P; Haas AV; Thompson CC
    Diabetes Care; 2018 May; 41(5):1106-1115. PubMed ID: 29678867
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy of the endoscopic duodenal-jejunal bypass liner prototype in severe or morbidly obese subjects implanted for up to 3 years.
    Quezada N; Muñoz R; Morelli C; Turiel D; Hernández J; Pimentel F; Escalona A
    Surg Endosc; 2018 Jan; 32(1):260-267. PubMed ID: 28664427
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.